Sophie Schuind

Sophie Schuind

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Critical Care
Verified
Journal Article
Open access
PDF file
AMAirton Leonardo de Oliveira Manoel
Airton Leonardo de Oliveira Manoel
AMAli Msheik
Ali Msheik
SSSophie Schuind
Sophie Schuind
GAGhaya Ibrahim Alrumaihi
Ghaya Ibrahim Alrumaihi
Fabio Silvio TacconeFabio Silvio Taccone
Fabio Silvio Taccone
Spontaneous intracerebral hemorrhage (ICH) remains the most devastating form of stroke, with limited evidence supporting surgical intervention. Traditional

30 June 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
ELEva Larranaga Lapique
Eva Larranaga Lapique
SGSalomé Gallemaers
Salomé Gallemaers
SSSophie Schuind
Sophie Schuind
CMChiara Mabiglia
Chiara Mabiglia
NYNicolas Yin
Nicolas Yin
MHMaya Hites
Maya Hites
Nocardia spp. is an environmental Gram-positive bacterium able to cause infections in humans, predominantly of an opportunistic nature. Nocardial brain abscesses are rare and result from dissemination from another primary lesion, mainly observed in immunocompromised hosts. The diagnosis of nocardiosis relies on direct examination and bacterial culture, but antimicrobial susceptibility testing (AST) remains controversial due to technical challenges, limited standardization, and a paucity of studies correlating in vitro susceptibility with clinical efficacy. Management is challenging and usually based on expert opinion, as robust evidence is limited. In this case report, we describe an immunocompromised patient with a Nocardia farcinica brain abscess who achieved clinical resolution following combination therapy that included ceftriaxone, despite in vitro resistance, illustrating the complexities in interpreting AST and guiding treatment decisions in rare infections.

6 December 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
CSClaudia Stella
Claudia Stella
AHAnas Hachlouf
Anas Hachlouf
LCLorenzo antonino Calabrò
Lorenzo antonino Calabrò
ICIrene Cavalli
Irene Cavalli
SSSophie Schuind
Sophie Schuind
Fabio Silvio TacconeFabio Silvio Taccone
Fabio Silvio Taccone
Background: Acetazolamide is a non-competitive inhibitor of carbonic anhydrase, an enzyme expressed in different cells of the central nervous system (CNS) and involved in the regulation of cerebral blood flow (CBF). The aim of this review was to understand the effects of acetazolamide on CBF, intracranial pressure (ICP) and brain tissue oxygenation (PbtO2) after an acute brain injury (ABI). Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA), we performed a comprehensive, computer-based, literature research on the PubMed platform to identify studies that have reported the effects on CBF, ICP, or PbtO2 of acetazolamide administered either for therapeutic or diagnostic purposes in patients with subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury, and hypoxic-ischemic encephalopathy. Results: From the initial search, 3430 records were identified and, through data selection, 11 of them were included for the qualitative analysis. No data on the effect of acetazolamide on ICP or PbtO2 were found. Cerebral vasomotor reactivity (VMR—i.e., the changing in vascular tone due to a vasoactive substance) to acetazolamide tends to change during the evolution of ABI, with the nadir occurring during the subacute stage. Moreover, VMR reduction was correlated with clinical outcome. Conclusions: This systematic review showed that the available studies on the effects of acetazolamide on brain hemodynamics in patients with ABI are scarce. Further research is required to better understand the potential role of this drug in ABI patients.